Dova Pharmaceuticals, Inc. Common Stock
DOVA
DOVA was delisted on the 11th of November, 2019.
48 hedge funds and large institutions have $209M invested in Dova Pharmaceuticals, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 6 reducing their positions, and 8 closing their positions.
183% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 6
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
30% more capital invested
Capital invested by funds: $160M → $209M (+$48.4M)
23% more funds holding
Funds holding: 39 → 48 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.55M |
| 2 |
Morgan Stanley
New York
|
+$5.58M |
| 3 |
PA
Perceptive Advisors
New York
|
+$1.51M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.24M |
| 5 |
PC
Pier Capital
Stamford,
Connecticut
|
+$1.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.26M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.9M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$425K |
| 4 |
Barclays
London,
United Kingdom
|
-$336K |
| 5 |
Millennium Management
New York
|
-$247K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NFA
51
Nationwide Fund Advisors
Columbus,
Ohio
| – | -$50K | -2,061 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$23K | -961 | Closed |
|
53
UBS Group
Zurich,
Switzerland
| – | -$2K | -94 | Closed |
|
|
MAM
54
Meeder Asset Management
Dublin,
Ohio
| – | -$2K | -62 | Closed |
|
|
STA
55
Summit Trail Advisors
New York
| – | +$192 | +7 | New |
|
56
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | +$932 | +34 | New |
|
DOVA Hedge Fund Activity: Q4 2017 in Review
48 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q4 2017, worth a combined $209M — up 30% from $160M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new DOVA positions and 8 closed out — a net gain of 9 holders — while 17 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $9.55M. The largest seller was Fidelity Investments, cutting an estimated $3.26M.
- 48 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q4 2017, up from 39 in Q3 2017.
- Funds reported $209M of Dova Pharmaceuticals, Inc. Common Stock stock for Q4 2017, up 30% quarter-over-quarter.
- 17 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q4 2017 and 8 closed out, a net change of +9 holders.
- The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q4 2017 was BlackRock, an estimated $9.55M added.
- The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q4 2017 was Fidelity Investments, an estimated $3.26M sold.
Based on aggregated 13F filings for Q4 2017.